Cinzia Baldessari

TL;DR: Outcomes of PS 2 NSCLC patients with PD-L1 TPS ≥50% receiving first-line pembrolizumab were globally dismal but strongly dependent on the reason conditioning the poor PS itself, and the only factor independently impacting on both PFS and OS.

TL;DR: Pembrolizumab was effective in a large cohort of NSCLC patients treated outside of clinical trials and it was confirmed that the absence of tobacco exposure, and the presence of bone and liver metastasis are associated with worse clinical outcomes to pembrolIZumab.

TL;DR: The molecular alterations underlying each of these EGFR TKIs resistance mechanisms are described, focusing on the currently available and future therapeutic strategies to overcome these phenomena.

TL;DR: This study confirms the feasibility and the safety of first-line, single-agent pembrolizumab, in a large, real-world cohort of patients with NSCLC with PD-L1 expression ≥ 50%.

TL;DR: Only a few case reports on SJS and TEN during treatment with either anti-PD1 alone or in combination with radiotherapy have been described, especially relevant considering that the use of such drugs in oncology is becoming more widespread in an ever-increasing number of cancer types.